FSDDF - FSD Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
9.09
0.00 (0.00%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close9.09
Open11.37
Bid0.00 x 0
Ask0.00 x 0
Day's Range9.09 - 9.09
52 Week Range3.93 - 56.88
Volume18,300
Avg. Volume7,329
Market Cap72.258M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • CNW Group

    FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020

    TORONTO , Jan. 17, 2020 /CNW/ - FSD Pharma Inc. (HUGE.CN) (HUGE.CN) (FRA: 0K9) ("FSD Pharma" or the "Company") is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari , along with the founders, members of the Company's Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Nasdaq Stock Market opening bell on Wednesday, January 22, 2020, at 9:30 am ET. The Opening Bell Ringing Ceremony will be held at Nasdaq's MarketSite in New York City and will be webcast live beginning at 9:20 am ET via the following link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony and live streaming will be available on Facebook at the following link: http://Facebook.com/Nasdaq. "It will indeed be a unique privilege for me to ring the opening bell at Nasdaq to commence trading in the presence of FSD Pharma's extended family and friends," said Raza Bokhari , MD, Executive Co-Chairman and CEO.

  • InvestmentPitch Media Video Discusses FSD Pharma's New Listing on the  Nasdaq Capital Market and Upcoming Biotech and Healthcare Conferences - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's New Listing on the Nasdaq Capital Market and Upcoming Biotech and Healthcare Conferences - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - January 10, 2020) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9), a specialty, biotech pharmaceutical R&D company, has started trading on the Nasdaq Capital Market under the symbol "HUGE". FSD Pharma is focused on developing, over time, a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of ...

  • Business Wire

    INSERTING and REPLACING FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’

    Insert in second paragraph, first sentence of release: Executive Co-Chairman and CEO.

  • FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'
    CNW Group

    FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'

    FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'

  • Business Wire

    FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol ‘HUGE’ on January 9, 2020

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") today announced that its Class B Subordinate Voting Shares (the "Shares") have been approved for listing on the NASDAQ Capital Market ("NASDAQ") under the symbol ‘HUGE’. Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020.

  • FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020
    CNW Group

    FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020

    Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020 . The Company's Shares will continue to be listed on the Canadian Securities Exchange under the symbol 'HUGE'.

  • Business Wire

    FSD Pharma Strengthens Management Team

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") today announced the appointments of three key executives: Donal Carroll, Chief Financial Officer. Mr. Carroll previously served as interim CFO; Sandra Lottes, Pharm D, Vice President & Head of Clinical Research of FSD Pharma’s BioSciences Division; and Shahzad Shah, Chief Operating Officer of FV Pharma.

  • InvestmentPitch Media Video Discusses FSD Pharma's Approval of Listing Application for Nasdaq Capital Market with trading Anticipated to Begin Shortly - Video Available on Investmentpitch.com
    Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's Approval of Listing Application for Nasdaq Capital Market with trading Anticipated to Begin Shortly - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - December 17, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), a specialty, biotech pharmaceutical R&D company, reports its application to list its Class B Subordinate Voting Shares on the Nasdaq Capital Market has been approved by Nasdaq and the company anticipates trading on Nasdaq to begin shortly. FSD Pharma is focused on developing a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of ...

  • FSD Pharma Receives Approval to List its Shares on Nasdaq
    CNW Group

    FSD Pharma Receives Approval to List its Shares on Nasdaq

    FSD Pharma Receives Approval to List its Shares on Nasdaq

  • Business Wire

    FSD Pharma Receives Approval to List Its Shares on Nasdaq

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Nasdaq has approved its application to have its Class B Subordinate Voting Shares (the "Shares") listed on the Nasdaq Capital Market ("Nasdaq"). FSD Pharma expects the Shares to commence trading on Nasdaq in the near future.

  • FSD Pharma to Present at Investor Summit on December 17
    CNW Group

    FSD Pharma to Present at Investor Summit on December 17

    Mr. Bokhari will be available during the day on December 17 for one-on-one meetings. Mr. Bokhari's presentation will be webcast live and available for replay on the 'Events and Presentations' section of the 'Investors' page of the FSD Pharma website, www.fsdpharma.com, or via https://www.webcaster4.com/Webcast/Page/2038/32606.

  • Business Wire

    FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Edward Brennan, MD, President, BioSciences Division, will present an overview of the Company at the 12th Annual LD Micro Main Event Investor conference at 12:20 p.m. PT/3:20 p.m. ET on Wednesday, December 11, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.

  • Business Wire

    FSD Pharma Reports Third Quarter 2019 Financial Results

    These financial results are unaudited, are prepared in accordance with International Financial Reporting Standards (IFRS) and are reported in Canadian dollars. The Company intends to initiate Phase 1 first-in-human safety and tolerability trials for its lead candidate, PP 101 micro-PEA during 1Q20.

  • FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering
    CNW Group

    FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering

    TORONTO , Nov. 4, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (OTCQB:FSDDD) (0K9.F) ("FSD" or the "Company") announces that it has closed a second tranche of its previously announced private placement (the "Private Placement"), and has now raised total gross proceeds of CAD $4,596,285 from investors, including members of senior management and the Board of Directors, issuing an aggregate of 228,671 class B subordinate voting shares (the "Shares"). The Shares issued to purchasers in Canada will be subject to a four-month hold period, in accordance with applicable Canadian securities laws. The Company expected to close the Private Placement by October 31, 2019 , however, it has elected to extend the Private Placement to accommodate potential additional interest from institutional grade investors.

  • FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018
    CNW Group

    FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018

    TORONTO , Oct. 23, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") announces that an amended and restated management's discussion and analysis for the year ended December 31, 2018 (the "Amended 2018 MD&A") has been filed on SEDAR to better comply with National Instrument 51-102 – Continuous Disclosure Obligations. The Amended 2018 MD&A was prepared following a continuous disclosure review by the Ontario Securities Commission ("OSC") of the Company's disclosure record. The Amended 2018 MD&A was filed to address comments received from OSC staff and in order to improve the Company's disclosure.

  • Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's New OTCQB Symbol and Appointment of Former U.S. Congressman Stephen Buyer to its Board of Directors - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 18, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDD) announced that its Class B shares, which trade on the OTCQB, will have a new symbol FSDDD for a period of 20 business days until November 13th, at which time the symbol will revert back to FSDDF. The temporary change is protocol for stocks that trade on US exchanges that undergo structural events, such as ...

  • Business Wire

    FSD Pharma Announces Temporary Change in OTCQB Ticker Symbol to FSDDD

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company”) today announced that the Company’s Class B Shares are trading on the OTCQB under the ticker symbol FSDDD for 20 business days, effective as of October 16, 2019. The temporary change is protocol for exchange stocks that undergo structural events, such as the 1:201 share consolidation announced by FSD Pharma on October 11, 2019 to advance the Company’s strategic plan to increase visibility among U.S. investors and list on a major U.S. exchange. FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis.

  • High Tide Announces Opening of 2nd KushBar Location Bringing its Total to 26 Branded Retail Cannabis Stores across Canada
    CNW Group

    High Tide Announces Opening of 2nd KushBar Location Bringing its Total to 26 Branded Retail Cannabis Stores across Canada

    CALGARY , Oct. 17, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that the KushBar retail store located in Unit #7 at 8807 100th Street in Morinville (the "KushBar Store") received its first delivery of cannabis products from Alberta Gaming, Liquor and Cannabis ("AGLC") and today will begin selling recreational cannabis products and accessories. To celebrate the grand opening of this location, festivities will take place at the KushBar Store on Saturday, October 19th .

  • FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation
    CNW Group

    FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation

    TORONTO , Oct. 11, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") today announced the appointment of former U.S. congressman Stephen Buyer to the Company's Board of Directors. The Company also announced that it will complete a consolidation of its class A multiple voting shares ("Class A Shares") and its class B subordinate voting shares ("Class B Shares" and collectively with the Class A Shares, the "FSD Shares"), each on a 1 to 201 basis (the "Consolidation").